294 related articles for article (PubMed ID: 30900482)
1. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
[No Abstract] [Full Text] [Related]
2. Drug Policy in Bulgaria.
Dimova A; Rohova M; Atanasova E; Kawalec P; Czok K
Value Health Reg Issues; 2017 Sep; 13():50-54. PubMed ID: 29073988
[TBL] [Abstract][Full Text] [Related]
3. PRICING, REIMBURSEMENT, AND HEALTH TECHNOLOGY ASSESSMENT OF MEDICINAL PRODUCTS IN BULGARIA.
Benisheva-Dimitrova T; Sidjimova D; Cherneva D; Kralimarkov N
Int J Technol Assess Health Care; 2017 Jan; 33(3):365-370. PubMed ID: 28831942
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
Hu J; Mossialos E
Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
[TBL] [Abstract][Full Text] [Related]
5. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
Davidova J; Praznovcova L; Lundborg CS
Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
[TBL] [Abstract][Full Text] [Related]
6. Drug Policy in Latvia.
Silins J; Szkultecka-Dębek M
Value Health Reg Issues; 2017 Sep; 13():73-78. PubMed ID: 29073995
[TBL] [Abstract][Full Text] [Related]
7. Drug Policy in Romania.
Radu CP; Pana BC; Furtunescu FL
Value Health Reg Issues; 2018 Sep; 16():28-32. PubMed ID: 29704726
[TBL] [Abstract][Full Text] [Related]
8. Drug Policy in Poland.
Jahnz-Różyk K; Kawalec P; Malinowski K; Czok K
Value Health Reg Issues; 2017 Sep; 13():23-26. PubMed ID: 29073983
[TBL] [Abstract][Full Text] [Related]
9. The 1996 pricing and reimbursement policy in The Netherlands.
de Vos CM
Pharmacoeconomics; 1996; 10 Suppl 2():75-80. PubMed ID: 10163439
[TBL] [Abstract][Full Text] [Related]
10. Drug Policy in Slovakia.
Bucek Psenkova M; Visnansky M; Mackovicova S; Tomek D
Value Health Reg Issues; 2017 Sep; 13():44-49. PubMed ID: 29073987
[TBL] [Abstract][Full Text] [Related]
11. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
12. Drug Policy in the Russian Federation.
Holownia-Voloskova M; Vorobiev PA; Grinin M; Davydovskaya MV; Ermolaeva TN; Kokushkin KA
Value Health Reg Issues; 2018 Sep; 16():106-111. PubMed ID: 30327255
[TBL] [Abstract][Full Text] [Related]
13. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
14. An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries.
Kamusheva M; Vassileva M; Savova A; Manova M; Petrova G
Front Public Health; 2018; 6():61. PubMed ID: 29556491
[TBL] [Abstract][Full Text] [Related]
15. Implementation of the 2011 Reimbursement Act in Poland: Desired and undesired effects of the changes in reimbursement policy.
Kawalec P; Sagan A; Stawowczyk E; Kowalska-Bobko I; Mokrzycka A
Health Policy; 2016 Apr; 120(4):356-61. PubMed ID: 26994865
[TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical expenditure and therapeutic value of new medicines in Spain.
Darba J
Pharmacoeconomics; 2003; 21(16):1211-2. PubMed ID: 14594440
[No Abstract] [Full Text] [Related]
17. Drug Policy in Estonia.
Mägi K; Lepaste M; Szkultecka-Dębek M
Value Health Reg Issues; 2018 Sep; 16():1-4. PubMed ID: 29529444
[TBL] [Abstract][Full Text] [Related]
18. Does drug price-regulation affect healthcare expenditures?
Ben-Aharon O; Shavit O; Magnezi R
Eur J Health Econ; 2017 Sep; 18(7):859-867. PubMed ID: 27696009
[TBL] [Abstract][Full Text] [Related]
19. The UK pharmaceutical market. An overview.
Towse A
Pharmacoeconomics; 1996; 10 Suppl 2():14-25. PubMed ID: 10163432
[TBL] [Abstract][Full Text] [Related]
20. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
